Nectar Lifesciences Share Price Today (NECLIFE)
TODAY IN ONE LINE
With a market cap of ₹199.12 Cr., it trades at a P/E of -0.80. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Nectar Lifesciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 51.8% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Price MomentumStock underperformed, dropping 40.2% over 1Y
- ●Sales ContractionQuarterly sales dropped 21.9% YoY
Latest Nectar Lifesciences News
What changed recently?
Recent events, corporate actions, and announcements.
Nectar Lifesciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Nectar Lifesciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Nectar Lifesciences Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Nectar Lifesciences Limited — derived from the live tape, not yesterday's close.
Nectar Lifesciences Limited last traded at ₹13.56 with an intraday range of ₹13.5–₹14.25 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹13.56| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 15.54 | +1.98 | +14.60% |
| R3 | 14.79 | +1.23 | +9.07% |
| R2 | 14.52 | +0.96 | +7.08% |
| R1 | 14.04 | +0.48 | +3.54% |
| PIVOT | 13.77 | 0.21 | 1.55% |
| CURRENT | 13.56 | — | — |
| S1 | 13.29 | -0.27 | -1.99% |
| S2 | 13.02 | -0.54 | -3.98% |
| S3 | 12.54 | -1.02 | -7.52% |
| S4 | 11.79 | -1.77 | -13.05% |
NECLIFE is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Below opening range, showing Bearishness
Nectar Lifesciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Nectar Lifesciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Nectar Lifesciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹199.12 Cr. and reported EPS of ₹-8.06.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,673 | — ▼ 100.0% |
| Sales Growth YoY %Derived | -0.74% | -100.00% |
| Other Income | 2 | 9 ▲ 391.3% |
| Total Income | 1,675 | 9 ▼ 99.4% |
| 1,368 | — ▼ 100.0% | |
| Gross ProfitDerived | 305 | — |
| Gross Margin %Derived | 18.23% | — |
| 332 | 61 ▼ 81.7% | |
| EBITDA (Operating Profit)Derived | -26 | — |
| OPM %Derived | -1.58% | — |
| 137 | 36 ▼ 73.4% | |
| Profit Before Tax (PBT) | -162 | -88 ▲ 45.6% |
| -48 | -31 ▲ 36.2% | |
| Effective Tax %Derived | 29.62% | 34.74% |
| Profit/Loss from Discontinued Ops | — | -236 |
| Total Profit for Period | -114 | -57 ▲ 49.6% |
| Net Profit (Owner's PAT)Derived | -114 | -57 ▲ 49.6% |
| Net Profit Margin %Derived | -6.79% | — |
| PAT Growth YoY %Derived | -2,376.07% | 49.55% |
| Earnings Per Share (EPS ₹) | -5.07 | -15.08 ▼ 197.4% |
| Diluted Shares Outstanding (Cr) | 22 | 19 ▼ 13.4% |
| Other Comprehensive Income (Net of Tax) | 1 | 0 ▼ 85.3% |
| Total Expenses (incl. D&A & Interest) | 1,836 | 97 ▼ 94.7% |
| Material Cost % of RevenueDerived | 74.76% | — |
| Employee Cost % of RevenueDerived | 5.77% | — |
| Other Cost % of RevenueDerived | 14.05% | — |
| Interest Coverage (x)Derived | -1.19x | — |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,901 | 2,783 ▲ 46.4% | 2,367 ▼ 15.0% | 1,544 ▼ 34.7% | 1,669 ▲ 8.1% | 1,525 ▼ 8.6% | 1,686 ▲ 10.6% | 1,673 ▼ 0.7% | — ▼ 100.0% | |
| Sales Growth YoY %Derived | — | 46.39% | -14.96% | -34.75% | 8.06% | -8.64% | 10.56% | -0.74% | -100.00% | |
| Other Income | 6 | 6 ▲ 6.6% | 4 ▼ 32.7% | 3 ▼ 32.0% | 11 ▲ 314.9% | 42 ▲ 274.0% | 13 ▼ 69.2% | 2 ▼ 85.5% | 9 ▲ 391.3% | |
| Total Income | 1,907 | 2,789 ▲ 46.3% | 2,371 ▼ 15.0% | 1,547 ▼ 34.7% | 1,680 ▲ 8.6% | 1,567 ▼ 6.7% | 1,699 ▲ 8.4% | 1,675 ▼ 1.4% | 9 ▼ 99.4% | |
1,367 | 2,218 ▲ 62.2% | 1,859 ▼ 16.2% | 1,157 ▼ 37.7% | 1,223 ▲ 5.7% | 1,159 ▼ 5.2% | 1,202 ▲ 3.7% | 1,368 ▲ 13.8% | — ▼ 100.0% | ||
| Gross ProfitDerived | 534 | 565 ▲ 5.8% | 508 ▼ 10.1% | 387 ▼ 23.8% | 446 ▲ 15.1% | 365 ▼ 18.0% | 483 ▲ 32.3% | 305 ▼ 36.9% | — | |
| Gross Margin %Derived | 28.09% | 20.31% | 21.47% | 25.08% | 26.71% | 23.96% | 28.68% | 18.23% | — | |
297 | 301 ▲ 1.2% | 288 ▼ 4.3% | 277 ▼ 3.8% | 287 ▲ 3.6% | 311 ▲ 8.4% | 330 ▲ 6.1% | 332 ▲ 0.4% | 61 ▼ 81.7% | ||
| EBITDA (Operating Profit)Derived | 237 | 264 ▲ 11.7% | 220 ▼ 16.7% | 110 ▼ 50.0% | 159 ▲ 44.0% | 54 ▼ 66.0% | 153 ▲ 183.8% | -26 ▼ 117.3% | — | |
| OPM %Derived | 12.45% | 9.50% | 9.30% | 7.13% | 9.50% | 3.54% | 9.08% | -1.58% | — | |
180 | 211 ▲ 17.8% | 187 ▼ 11.7% | 147 ▼ 21.2% | 136 ▼ 7.6% | 139 ▲ 2.1% | 148 ▲ 6.7% | 137 ▼ 7.4% | 36 ▼ 73.4% | ||
| Profit Before Tax (PBT) | 63 | 59 ▼ 6.2% | 37 ▼ 36.3% | -85 ▼ 326.2% | 34 ▲ 140.2% | -42 ▼ 224.5% | 18 ▲ 143.1% | -162 ▼ 984.2% | -88 ▲ 45.6% | |
10 | 11 ▲ 7.8% | 6 ▼ 49.4% | -12 ▼ 302.4% | 9 ▲ 178.5% | -18 ▼ 301.9% | 13 ▲ 172.8% | -48 ▼ 460.5% | -31 ▲ 36.2% | ||
| Effective Tax %Derived | 16.61% | 19.08% | 15.16% | 13.57% | 26.51% | 42.99% | 72.66% | 29.62% | 34.74% | |
| Profit/Loss from Discontinued Ops | — | — | — | — | — | — | — | — | -236 | |
| Total Profit for Period | 52 | 48 ▼ 8.9% | 32 ▼ 33.2% | -73 ▼ 330.5% | 25 ▲ 134.2% | -24 ▼ 196.6% | 5 ▲ 120.7% | -114 ▼ 2376.1% | -57 ▲ 49.6% | |
| Net Profit (Owner's PAT)Derived | 52 | 48 ▼ 8.9% | 32 ▼ 33.2% | -73 ▼ 330.5% | 25 ▲ 134.2% | -24 ▼ 196.6% | 5 ▲ 120.7% | -114 ▼ 2376.1% | -57 ▲ 49.6% | |
| Net Profit Margin %Derived | 2.75% | 1.71% | 1.34% | -4.74% | 1.50% | -1.59% | 0.30% | -6.79% | — | |
| PAT Growth YoY %Derived | — | -8.94% | -33.22% | -330.47% | 134.19% | -196.55% | 120.65% | -2,376.07% | 49.55% | |
| Earnings Per Share (EPS ₹) | 2.33 | 2.12 ▼ 9.0% | 1.42 ▼ 33.0% | -3.27 ▼ 330.3% | 1.12 ▲ 134.3% | -1.08 ▼ 196.4% | 0.22 ▲ 120.4% | -5.07 ▼ 2404.5% | -15.08 ▼ 197.4% | |
| Diluted Shares Outstanding (Cr) | 22 | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 22 ▲ 0.0% | 19 ▼ 13.4% | |
| Other Comprehensive Income (Net of Tax) | 1 | 0 ▼ 76.4% | 1 ▲ 110.6% | 0 ▼ 24.6% | 1 ▲ 108.0% | 1 ▲ 5.2% | -0 ▼ 139.1% | 1 ▲ 258.2% | 0 ▼ 85.3% | |
| Total Expenses (incl. D&A & Interest) | 1,844 | 2,730 ▲ 48.1% | 2,333 ▼ 14.5% | 1,632 ▼ 30.1% | 1,646 ▲ 0.9% | 1,609 ▼ 2.2% | 1,680 ▲ 4.4% | 1,836 ▲ 9.3% | 97 ▼ 94.7% | |
| Material Cost % of RevenueDerived | 72.68% | 79.96% | 77.49% | 66.59% | 72.32% | 78.76% | 73.71% | 74.76% | — | |
| Employee Cost % of RevenueDerived | 4.12% | 2.87% | 3.42% | 4.75% | 4.47% | 5.10% | 5.02% | 5.77% | — | |
| Other Cost % of RevenueDerived | 11.52% | 7.94% | 8.75% | 13.19% | 12.74% | 15.32% | 14.57% | 14.05% | — | |
| Interest Coverage (x)Derived | 1.50x | 1.36x | 1.27x | 0.45x | 1.29x | -0.07x | 1.06x | -1.19x | — |
Nectar Lifesciences segment analysis : revenue and profit mix.
Disclosed business segments at Nectar Lifesciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Nectar Lifesciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Nectar Lifesciences Limited.
Our AI distills the core fundamental drivers supporting Nectar Lifesciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Nectar Lifesciences Limited's investment case rests on 3 positive markers and 3 flagged concerns drawn from the latest reported filings.
What you're getting.
Despite recent losses, Nectar Lifesciences shows a history of profitability, with net profits reaching 11.66 in the March 2022 quarter. This suggests potential for future recovery and improved financial performance.
Promoter holding has remained relatively stable at around 55% historically, indicating a degree of confidence in the company's long-term prospects, even with recent fluctuations.
The company operates in the growing Pharmaceuticals sector within the Healthcare industry, offering potential for long-term growth and market share expansion, despite current challenges.
Key Risks.
Nectar Lifesciences exhibits significant losses in recent quarters, with a negative net profit of -130 in the latest quarter and a substantial -22149% quarterly profit variation. This raises serious concerns about its financial health.
The company has a high debt-to-equity ratio of 0.61, indicating a considerable reliance on debt financing, which could increase financial risk and vulnerability to economic downturns.
The stock price has experienced significant volatility, falling from a high of 56.50 to a low of 13.00, indicating investor uncertainty and potential for further price declines. This volatility is a major risk for investors.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Nectar Lifesciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Nectar Lifesciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Nectar Lifesciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Nectar Lifesciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Nectar Lifesciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Nectar Lifesciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Nectar Lifesciences Limited stood at 70.1% of traded volume, against a 20-day average of 63.7%.
Nectar Lifesciences announcements: results, concalls, ratings, M&A.
Filings Nectar Lifesciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Nectar Lifesciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 100 documents below.
General Updates
Nectar Lifesciences Limited has informed the Exchange about Update On Slump Sale
General Updates
Nectar Lifesciences Limited has informed the Exchange about change in the registered office of the Company
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Nectar Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Copy of Newspaper Publication
Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Copy of Newspaper Publication
Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Nectar Lifesciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Nectar Lifesciences has declared, sequenced by announce and record date.
Nectar Lifesciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Nectar Lifesciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Nectar Lifesciences as reported to SEBI — buying and selling signals from the people who know the business best.
Nectar Lifesciences insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| RAMAN GOYAL | Insider | 19 Dec 2024 | buy | +4.00 L | ₹1.77 Cr. | ₹44.37 |
About Nectar Lifesciences Limited: business, sector, key facts.
What Nectar Lifesciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Nectar Lifesciences Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: NECLIFE, BSE: 532649.
Nectar Lifesciences Limited, operating under the name NECLIFE, is a pharmaceutical company based in Chandigarh, India, with both domestic and international operations. Their core business revolves around the manufacturing and sale of pharmaceutical products, focusing heavily on the Cephalosporin class of antibiotics.
A significant portion of NECLIFE's business involves the production of Active Pharmaceutical Ingredients (APIs) and intermediates. These APIs form the building blocks of many finished medications and include a wide range of cephalosporins such as cefixime, cefuroxime axetil (in both amorphous and crystalline forms), cefotaxime sodium, ceftriaxone sodium, and several others. This demonstrates a specialization in the production of key components for a specific antibiotic family.
Beyond API manufacturing, NECLIFE offers contract manufacturing services for finished dosage forms. This means the company produces finished medications for other pharmaceutical companies, expanding their business model beyond just providing raw materials. The finished dosage forms they manufacture include tablets, capsules, dry powder oral suspensions, granules, and injectables, primarily focusing on cephalosporin-based medications based on their API production strengths.
In addition to their core pharmaceutical business, NECLIFE also produces and sells menthol and pearl capsules, indicating some diversification into other areas of the pharmaceutical and possibly supplement markets. This suggests a strategy to broaden their product portfolio and potentially target different market segments.
Established in 1995, NECLIFE has built a considerable presence in the pharmaceutical industry, demonstrating expertise in both API production and finished dosage form manufacturing. Their focus on cephalosporin antibiotics, coupled with contract manufacturing services, suggests a strategic approach to leverage their manufacturing capabilities and cater to the demands of a broad customer base.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Nectar Lifesciences Limited (NECLIFE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Nectar Lifesciences Limited (NECLIFE)?
The current share price of Nectar Lifesciences Limited (NECLIFE) is ₹13.56. Today, the stock has declined by ₹0.80 (5.57%), trading in a range of ₹13.5 to ₹14.25. The stock opened at ₹14.18 with a trading volume of 7,00,336 shares.
02Is Nectar Lifesciences Limited stock a good investment for long-term?
Nectar Lifesciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹199.12 crores, P/E ratio of -0.80, ROE of -9.85%, and ROCE of -5.36%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Nectar Lifesciences Limited stock?
The 52-week high price of Nectar Lifesciences Limited (NECLIFE) is ₹21.4, while the 52-week low is ₹9.3. Currently trading at ₹13.56, the stock is 35.2% away from its 52-week low and 36.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Nectar Lifesciences Limited stock at the current price?
Whether to buy Nectar Lifesciences Limited stock at ₹13.56 depends on multiple factors. The stock is currently trading with a P/E ratio of -0.80 and P/B ratio of 0.40. Today's performance shows a loss of 5.57%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Nectar Lifesciences Limited and when is the next dividend?
Nectar Lifesciences Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹13.56, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Nectar Lifesciences Limited?
Nectar Lifesciences Limited's key financial metrics include: P/E Ratio: -0.80, P/B Ratio: 0.40, ROE: -9.85%, ROCE: -5.36%, Dividend Yield: 0.00%, EPS: ₹-8.06, Book Value: ₹42.63, and Debt-to-Equity: 0.00. The company's market cap stands at ₹199.12 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Nectar Lifesciences Limited stock performing today in the market?
Nectar Lifesciences Limited stock opened at ₹14.18 and is currently trading at ₹13.56, showing a decline of ₹0.80 (5.57%). The intraday high is ₹14.25 and low is ₹13.5. The trading volume stands at 7,00,336 shares, indicating moderate market participation today.
08What is the P/E ratio of Nectar Lifesciences Limited and what does it indicate?
Nectar Lifesciences Limited has a Price-to-Earnings (P/E) ratio of -0.80, which means investors are willing to pay ₹-0.80 for every ₹1 of earnings. With an EPS of ₹-8.06, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Nectar Lifesciences Limited (NECLIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.